Grit Bio, Inc.

GritBIO is the solution to the next generation of cancer therapeutics. Through the development of peptide technologies, which target the metabolism of cancer, GritBIO is able to offer a safer approach to treating squamous cell carcinoma of the pharynx. GritBIO is also currently researching novel biological inhibitors for SARS-CoV-2. The research currently being conducted positions our company at the cutting edge of solutions for today's most salient problems.